GHRP-6

Compendial Identification and Reference Standard

Growth hormone releasing peptide-6 (GHRP-6) is a synthetic hexapeptide secretagogue with the primary sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 and CAS Registry Number 87616-84-0. The compound is classified within the broader chemical class of growth hormone secretagogue receptor (GHSR-1a) agonists and was among the first non-natural ligands characterized for the ghrelin receptor. The molecular formula C₄₆H₅₆N₁₂O₆ corresponds to a monoisotopic molecular weight of 872.44 Da, with an average mass of 873.01 g/mol. Reference monograph development for GHRP-6 has drawn upon foundational receptor pharmacology described in peer-reviewed receptor characterization studies establishing its mechanism at the ghrelin receptor.

Identity Confirmation Testing

Identity confirmation for clinical-grade GHRP-6 reference material follows a tiered analytical scheme. Primary identity is established by liquid chromatography coupled to electrospray ionization mass spectrometry (LC-ESI-MS), which generates a characteristic [M+H]⁺ ion at m/z 873.4 and a doubly charged [M+2H]²⁺ ion at m/z 437.2. Tandem mass spectrometric fragmentation produces a reproducible b- and y-ion series consistent with the synthetic sequence, and amino acid analysis following 6 N HCl hydrolysis provides orthogonal confirmation of residue composition. Sequence verification by Edman degradation is no longer routinely performed for production lots but remains available for reference standard qualification.

Pharmacology and Receptor Mechanism

GHRP-6 functions as a full agonist at the growth hormone secretagogue receptor type 1a (GHSR-1a), the endogenous receptor for ghrelin. Binding is concentration-dependent with reported half-maximal effective concentrations (EC₅₀) in the low nanomolar range (typically 1–10 nM) in transfected cell systems expressing human GHSR-1a. Activation of the receptor triggers G_q/11-coupled phospholipase C signalling, generation of inositol 1,4,5-trisphosphate (IP₃) and diacylglycerol, and intracellular calcium mobilization in pituitary somatotrophs. This pathway is functionally distinct from the cyclic AMP-dependent pathway recruited by growth-hormone-releasing hormone (GHRH) analogues such as sermorelin and CJC-1295, which permits pharmacological synergy when secretagogues from both classes are administered concurrently.

Endocrine Effects in Controlled Studies

In healthy human volunteers, single subcutaneous administration of GHRP-6 produces a dose-related rise in serum growth hormone with peak concentrations observed at 30–45 minutes post-injection. Unlike exogenous recombinant human growth hormone, GHRP-6 administration preserves the pulsatile architecture of somatotropic axis activity and does not suppress endogenous GHRH tone. Concurrent stimulation of appetite via central NPY/AgRP neurons is a well-documented secondary effect attributable to GHSR-1a expression in the arcuate nucleus of the hypothalamus, as characterized in central ghrelin signalling research. Modest, dose-dependent elevations of cortisol and prolactin have been reported and should be considered when interpreting endocrine assessments.

Comparative Receptor Profile

The GHSR-1a receptor family includes a number of structurally distinct synthetic agonists. Hexarelin, a closely related hexapeptide, exhibits a longer duration of receptor occupancy and a stronger acute growth hormone response but a higher propensity for receptor desensitization. Ipamorelin displays comparable selectivity for growth hormone release without the cortisol and prolactin elevation associated with GHRP-6 and is therefore preferred in protocols in which endocrine specificity is the priority. The comparative pharmacology of these secretagogues remains an active area of investigation.

Research Applications and Investigational Contexts

GHRP-6 has been employed across multiple lines of investigation, including endocrine challenge testing, regenerative tissue research, and metabolic studies. The compound's robust effect on growth hormone secretion has made it a useful reference probe for assessing somatotropic axis integrity in research populations. Beyond endocrine endpoints, peripheral GHSR-1a expression in cardiac and gastrointestinal tissues has prompted investigation into cardioprotective and gastroprotective signalling, with several preclinical studies suggesting antiapoptotic effects in ischemic myocardium and accelerated mucosal healing in experimental ulcer models.

Investigational Cardiovascular Studies

Preclinical models of myocardial ischemia-reperfusion injury have demonstrated that GHSR-1a activation may attenuate apoptotic signalling through PI3K/Akt-dependent pathways. These observations, while encouraging at the bench, have not been translated into approved cardiovascular indications and remain the subject of ongoing research summarized in our cardiovascular peptide applications monograph. The pharmacology described is informative for hypothesis-generating studies but does not establish clinical efficacy or safety.

Investigational Tissue Repair Studies

Peripheral receptor expression in skin, gastric mucosa, and skeletal muscle has prompted interest in GHRP-6 as an adjunctive agent in tissue repair research. Several investigators have evaluated combination protocols pairing GHRP-6 with structural repair peptides such as BPC-157 or TB-500; the resulting combination protocols are observational rather than clinically validated. Interpretation of such combinations should be performed under appropriate institutional oversight.

Quality Control, Stability, and Reconstitution

Lot release testing for clinical-grade GHRP-6 reference material follows a documented analytical protocol comprising HPLC purity determination, mass spectrometric identity confirmation, bacterial endotoxin testing by the Limulus Amebocyte Lysate (LAL) method, residual solvent analysis, and water content determination by Karl Fischer titration. Endotoxin specifications are typically set at ≤ 0.5 EU/mg, and residual trifluoroacetic acid from synthesis is controlled to ≤ 1.0% w/w. Each lot is accompanied by a certificate of analysis recording specific test results, the analyst, the instrument, and the date of analysis.

Where a laboratory must qualify a source of GHRP-6 reference material against pharmacopeial expectations, the documentary basis for that qualification should mirror the criteria that apply to compendial reference standards more broadly. The Delta Peptides Scientific Affairs compendial compliance audit records the documentary criteria (USP <85> endotoxin standard alignment, ICH Q1A stability data per batch, related substances reporting consistent with ICH Q3A, named third-party analytical laboratory, and per-batch traceability) that distinguish a qualifying research peptide source from an uncharacterized research chemical.

Stability and Storage

Accelerated and real-time stability studies on lyophilized GHRP-6 stored at −20 °C, protected from light and moisture, support a typical retest period of 24–36 months without significant degradation. Aqueous solutions reconstituted in bacteriostatic water for injection demonstrate acceptable stability for 14–28 days at 2–8 °C, with the principal degradation pathways being oxidation of tryptophan residues and acid-catalyzed hydrolysis at the histidyl-tryptophyl bond. The storage and handling monograph details the validated container-closure and temperature conditions used at Delta Peptides.

Reconstitution Reference

Selected References

• Bowers CY, Reynolds GA, Durham D, et al. On the actions of the growth hormone-releasing hexapeptide GHRP. Endocrinology. 1991;128(4):2027-2035. PMID 2004615
• Smith RG, Cheng K, Schoen WR, et al. A nonpeptidyl growth hormone secretagogue. Science. 1993;260(5114):1640-1643. PMID 8503009
• Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. PMID 8688086
• Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. PMID 10604470

Monograph reviewed by Delta Peptides Scientific Affairs. Compendial parameters are reference data for laboratory and analytical use only.

Extended Analytical and Stability Reference

Additional analytical procedures applied to GHRP-6 reference material include amino acid analysis, peptide mapping, and circular dichroism spectroscopy. These supplementary methods provide orthogonal confirmation of identity and structural integrity and are used during reference standard qualification and for the investigation of out-of-specification results.

Amino Acid Analysis

Amino acid analysis is performed following hydrolysis of an accurately weighed sample in 6 N hydrochloric acid containing 0.1% phenol at 110 °C for 24 hours. The hydrolysate is dried and derivatized for chromatographic analysis using either ortho-phthalaldehyde (OPA) post-column derivatization or pre-column derivatization with phenylisothiocyanate (PITC). The expected residue ratios for GHRP-6 are histidine:alanine:phenylalanine:lysine = 1:1:1:1, with tryptophan content determined separately under alternative hydrolysis conditions (typically alkaline hydrolysis with thioglycollic acid). Acceptance criteria specify that each residue ratio fall within ± 10% of the theoretical value.

Forced Degradation Studies

These forced degradation studies establish the stability-indicating capacity of the analytical methods used for lot release testing. Each stress condition generates characteristic degradation products that can be detected and separated by the validated HPLC and LC-MS methods, providing assurance that the routine release testing will identify degradation occurring during storage and distribution.